Mesenchymal Stem Cell Therapy in Ischemic Stroke: A Meta-analysis of Preclinical Studies

Deepaneeta Sarmah, Vishal Agrawal, Pallavi Rane, Shashikala Bhute, Mitsuyoshi Watanabe, Kiran Kalia, Zhumur Ghosh, Kunjan R Dave, Dileep R Yavagal, Pallab Bhattacharya

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Numerous preclinical studies have been carried out using mesenchymal stem cells (MSCs) therapy for ischemic stroke. The purpose of the present meta-analysis is to review the quality of preclinical studies. In all, 4,361 articles were identified, out of which 64 studies were included (excluding in vitro studies). The results were obtained across species, route, and time of administration, immunogenicity, and doses. The median quality score 4.90/10, confidence interval 95%, and large effect size were observed, which strongly supports the translation potential of MSC therapy for ischemic stroke.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StateAccepted/In press - Jan 1 2017

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Mesenchymal Stem Cell Therapy in Ischemic Stroke: A Meta-analysis of Preclinical Studies'. Together they form a unique fingerprint.

  • Cite this

    Sarmah, D., Agrawal, V., Rane, P., Bhute, S., Watanabe, M., Kalia, K., Ghosh, Z., Dave, K. R., Yavagal, D. R., & Bhattacharya, P. (Accepted/In press). Mesenchymal Stem Cell Therapy in Ischemic Stroke: A Meta-analysis of Preclinical Studies. Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.927